ACS
ADAP

Archford Capital Strategies’s Adaptimmune Therapeutics ADAP Stock Holding History

Archford Capital Strategies’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,000
Closed -$4K – 216
2019
Q2 		$4K Buy
+1,000
New +$4.08K ﹤0.01% 473

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Archford Capital Strategies's ADAP Position: Q3 2019 in Review

Archford Capital Strategies sold out of Adaptimmune Therapeutics (ADAP) in Q3 2019, closing a stake of 1,000 shares — an estimated $4K sold.

Archford Capital Strategies first reported a position in ADAP in Q2 2019 and held it in 1 quarter. The position peaked at $4K in Q2 2019. 49 funds tracked by Wall St. Rank hold ADAP as of Q3 2019.

  • Archford Capital Strategies reported no remaining Adaptimmune Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Archford Capital Strategies sold 1,000 Adaptimmune Therapeutics shares in Q3 2019, an estimated $4K.
  • Archford Capital Strategies first reported a position in Adaptimmune Therapeutics in Q2 2019 and held it in 1 quarter.
  • Archford Capital Strategies's Adaptimmune Therapeutics position peaked at $4K in Q2 2019.
  • 49 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2019.

Based on Archford Capital Strategies's 13F filing for Q3 2019, filed 23 Oct 2019.